NasdaqCM - Delayed Quote • USD
Inovio Pharmaceuticals, Inc. (INO)
At close: 4:00 PM EDT
After hours: 4:05 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 3 |
| Avg. Estimate | -0.99 | -0.97 | -3.93 | -3.39 |
| Low Estimate | -1.17 | -1.15 | -4.64 | -4.41 |
| High Estimate | -0.86 | -0.82 | -3.2 | -2.85 |
| Year Ago EPS | -1.92 | -1.56 | -6.09 | -3.93 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 5 | 4 |
| Avg. Estimate | 190k | 190k | 600k | 7.02M |
| Low Estimate | 100k | 100k | -- | -- |
| High Estimate | 250k | 250k | 1M | 17.08M |
| Year Ago Sales | 114k | 226k | 832k | 600k |
| Sales Growth (year/est) | 66.70% | -15.90% | -27.90% | 1,070.00% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -1.74 | -1.74 | -1.52 | -1.27 |
| EPS Actual | -1.92 | -1.56 | -1.56 | -1.12 |
| Difference | -0.18 | 0.18 | -0.04 | 0.15 |
| Surprise % | -10.30% | 10.30% | -2.60% | 11.80% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.99 | -0.97 | -3.93 | -3.39 |
| 7 Days Ago | -0.99 | -0.97 | -3.93 | -3.39 |
| 30 Days Ago | -0.99 | -0.97 | -3.93 | -3.39 |
| 60 Days Ago | -0.83 | -0.8 | -3.57 | -2.64 |
| 90 Days Ago | -0.07 | -0.07 | -0.3 | -0.25 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | INO | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 48.40% | -- | -- | 1.60% |
| Next Qtr. | 37.80% | -- | -- | 10.50% |
| Current Year | 35.50% | -- | -- | 5.20% |
| Next Year | 13.70% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 41.50% | -- | -- | 11.22% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Maintains | Oppenheimer: Outperform to Outperform | 3/8/2024 |
| Reiterates | RBC Capital: Sector Perform to Sector Perform | 3/7/2024 |
| Upgrade | Oppenheimer: Perform to Outperform | 1/25/2024 |
Related Tickers
NVAX Novavax, Inc.
3.9700
+2.06%
VXRT Vaxart, Inc.
0.7556
-10.29%
MRNS Marinus Pharmaceuticals, Inc.
1.3800
-2.13%
LGVN Longeveron Inc.
1.9200
-4.48%
VNDA Vanda Pharmaceuticals Inc.
5.11
+2.82%
SRNE Sorrento Therapeutics, Inc.
0.0200
-16.67%
JAGX Jaguar Health, Inc.
0.1569
-11.41%
PALI Palisade Bio, Inc.
4.7100
-7.10%
OCGN Ocugen, Inc.
1.3200
0.00%
ADIL Adial Pharmaceuticals, Inc.
1.9300
-11.06%